Back to directory
AI-powered diagnostic tools for diabetic retinopathy at point-of-care
Built from URLHealthcareMedical DevicesAutomationDigital healthAIHealthTech
See something off about this company?
AI-powered diagnostic tools for diabetic retinopathy at point-of-care
Built from URLDigital Diagnostics is a pioneering AI diagnostics company on a mission to transform the quality, accessibility and affordability of healthcare. Founded and led by Dr. Michael Abramoff, an ophthalmologist, neuroscientist and computer engineer, Digital Diagnostics developed a patented biomarker-based approach to build autonomous algorithms that make clinical decisions without human intervention. Digital Diagnostics and its flagship product IDx-DR, an autonomous AI system FDA-authorized to diagnose diabetic retinopathy and diabetic macular edema, has proven that intelligent diagnostic platforms can be used safely, efficiently and equitably to improve patient outcomes. As it expands into other diagnostic capabilities, Digital Diagnostics has paved the way for automated diagnosis to become a new standard of care that will contribute significantly to democratizing healthcare.
See something off about this company?
Many patients with diabetes lack access to specialty eye care and miss critical diabetic retinopathy screenings, leading to preventable vision loss and blindness. Traditional screening methods create care gaps and delays in diagnosis.
LumineticsCore is an FDA-cleared autonomous AI diagnostic platform that provides immediate diabetic retinopathy diagnosis at the point-of-care in primary care settings. The system delivers results within 30 seconds of image submission and is reimbursable under CPT code 92229.
Digital Diagnostics was the first company to receive FDA clearance for AI diagnostic platform without physician input. Case studies show significant improvements in screening rates, with one clinic increasing adherence from 16.2% to 50.7% and another exceeding 90th percentile HEDIS benchmarks.